Personalized neoantigen-pulsed autologous dendritic cells in newly-diagnosed glioblastoma: a phase Ib trial
A personalized vaccine approach shows early promise in glioblastoma, a brain cancer with no cure, opening new possibilities for training the immune system to fight this aggressive disease.
A Phase Ib trial in newly-diagnosed glioblastoma evaluated personalized neoantigen-pulsed autologous dendritic cells, demonstrating safety in this highly refractory tumor type with extreme unmet need. Published in Nature Communications, the trial provides early clinical evidence supporting further development of neoantigen-directed DC vaccines in GBM, where no curative therapies currently exist.
What the study was
- Study design
- Phase Ib clinical trial of personalized neoantigen-pulsed autologous dendritic cell immunotherapy in newly-diagnosed GBM
- Population
- Newly-diagnosed glioblastoma patients
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Nat Commun
Why it surfaced
Phase Ib trial of personalized neoantigen DC therapy in GBM published in Nat Commun; addresses highest-unmet-need brain tumor with novel personalized immunotherapy strategy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.